Clinical trials have demonstrated the efficacy of durvalumab in improving progression-free survival and overall survival in certain cancer types. For example, in NSCLC, the PACIFIC trial showed that durvalumab significantly extended the time patients lived without their disease worsening. This makes it a valuable treatment option, particularly for patients with limited alternatives.
